Results 91 to 100 of about 1,443,667 (357)

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

Clinical Cancer Research, 2020
Purpose: Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy.
Matthew Kraman, Mustapha Faroudi, N. Allen, K. Kmiecik, D. Gliddon, Claire J Seal, A. Koers, M. Wydro, Sarah Batey, J. Winnewisser, L. Young, M. Tuna, J. Doody, Michelle Morrow, N. Brewis   +14 more
semanticscholar   +1 more source

Bioorthogonal Reaction of o‐Quinone with Furan‐2(3H)‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes

Advanced Science, EarlyView.
A site‐selective, efficient, and mild tyrosine conjugation via tyrosinase oxidation and nucleophilic addition, allowing for site‐selective functionalization of peptides, recombinant proteins, and IgGs. Site‐selective mono‐functionalization of IgGs at Y296 enables the construction of immunoliposomes.
Hongfei Chen, Zhiyi Xu, Yishu Bao, Farshad Shiri, Dingdong Yuan, Yuke Hu, Biquan Li, Bin Zeng, Xiaojing Li, Hao Kong, Zikang Wang, Wilson Chun‐Yu Lau, Zhenyang Lin, Jiang Xia   +13 more
wiley   +1 more source

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

Nature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku, Xuping Xie, Jianqing Lin, Peng Gao, Bin Wu, Abbas El Sahili, Hang Su, Yang Liu, Xiaohua Ye, Eddie Yongjun Tan, Xin Li, Xuejun Fan, Boon Chong Goh, Wei Xiong, Hannah Boyd, Antonio E. Muruato, Hui Deng, Hongjie Xia, Jing Zou, Birte K. Kalveram, Vineet D. Menachery, Ningyan Zhang, Julien Lescar, Pei-Yong Shi, Zhiqiang An   +24 more
doaj   +1 more source

Enhancing the Protein Stability of an Anticancer VHH‐Fc Heavy Chain Antibody through Computational Modeling and Variant Design

Advanced Science, EarlyView.
In this study, a computational pipeline is developed to systematically evaluate the conformational stability, disulfide bond reduction state, and aggregation and degradation tendencies of an anticancer VHH‐Fc fusion antibody. Based on the mechanistic insights, antibody variants with enhanced stability and increased yield are successfully designed. This
Yuan Fang, Menghua Song, Tianning Pu, Xiaoqing Song, Kailu Xu, Pengcheng Shen, Ting Cao, Yiman Zhao, Simon Hsu, Dongmei Han, Qiang Huang   +10 more
wiley   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
doaj   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Advanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde   +3 more
wiley   +1 more source

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning [PDF]

arXiv, 2020
The fast and untraceable virus mutations take lives of thousands of people before the immune system can produce the inhibitory antibody. Recent outbreak of novel coronavirus infected and killed thousands of people in the world. Rapid methods in finding peptides or antibody sequences that can inhibit the viral epitopes of COVID-19 will save the life of ...
arxiv  

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

Advanced Science, EarlyView.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang, Xinyu Qiu, Xiaoning Tong, Shaoju Gan, Weicheng Yi, Sitao Xie, Xiangsheng Liu, Chao Zuo, Weihong Tan   +8 more
wiley   +1 more source

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

mAbs
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.
Alyssa Synan, Nila C. Wu, Roberto Velazquez, Thomas Gesner, Claude Logel, Kathrin Mueller, Andrew Green, Patrizia Barzaghi-Rinaudo, Quincey Simmons, Samuele Mercan, Xingyi Shi, Xun Li, Vivek Sagar, Joshua Korn, Margaret McLaughlin, William R. Tschantz, Dominik Hainzl, Anthony Malamas, Thomas Huber, Regis Cebe, Kathleen T. Xie, Joseph A. D’Alessio   +21 more
doaj   +1 more source